Latest Industry Insights

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

A specialist in flow cytometry, cell sorting and cellular biology, Dr. Richard Cuthbert shared his perspectives on the current and future applications of flow cytometry – and automated flow cytometry systems – in modern drug discovery.

Dr. Bo Wiinberg, chief business development officer at the Novo Nordisk Foundation Cellerator, discusses the current obstacles halting advances in stem cell-based cell therapies and what can be done to overcome them.

bit.bio’s GFP ioMicroglia enables real-time tracking of microglia in complex co-cultures and in vivo, streamlining neurodegeneration research and drug discovery.

To learn about the progress being made in the RNA therapeutics space, we spoke to CTO and Co-Founder of La Jolla Labs, Jeff Milton, at the 2025 SLAS international meeting in San Diego.

UK Biocentre is adopting Azenta’s BioArc™ Ultra™, an automated -80°C storage system, to enhance biobanking efficiency and sustainability. With high-density storage and precise temperature control, it safeguards valuable samples.

Louise Digby, vice president of enzymes and bioproduction at BioProduction by SEKISUI, discusses some of the current challenges in scaling microbial fermentation for biopharmaceutical production and how a CDMO can help overcome these challenges.

A new collaborative trial is exploring how music and VR could provide a personalized anxiety treatment. Technology Networks spoke with the team behind the trial to learn more.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.